Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

P eople with pockets of fat hidden inside their muscles are at a higher risk of dying or being hospitalised from a heart ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...